Replication-deficient herpes simplex virus type 1 virus vaccine
By developing a replication-deficient HSV-1 virus vaccine, including antigens fused with SARS-Cov, SARS-Cov-2 and their variant spike glycoproteins, the impact of existing vaccines on new variants and protection of multiple sabeviruses has been solved, and broad-spectrum immune protection and long-lasting neutralizing antibody effects have been achieved.
CN119730878AInactive Publication Date: 2025-03-28IMMVIRA BIOPHARMACEUTICALS CO LTD
0 Cites 0 Cited by
Patent Information
- Application Number
- CN202380055550.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-05
- Filing Date
- 2023-08-04
- Publication Date
- 2025-03-28
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Technical Problem
Existing COVID-19 vaccines may be affected by new variants and are difficult to provide broad-spectrum immune protection against multiple sabeviruses.
Method used
A replication-deficient HSV-1 virus vaccine is developed that contains the modified HSV-1 genome and at least one antigen driven by the promoter of the wild-type HSV-1 immediate early gene and fused into the HSV-1 glycoprotein, including the spike glycoprotein domains of SARS-Cov, SARS-Cov-2 and its variants.
Benefits of technology
The vaccine is able to induce an immune response against sabavirus in subjects, providing durable neutralizing antibodies for up to at least 6 months, adapting to broad-spectrum protection against a variety of sabavirus variants.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention discloses a replication-deficient HSV-1 (herpes simplex virus type 1) virus vaccine. The replication-deficient HSV-1 virus vaccine comprises a modified HSV-1 genome and at least one antigen. The modification includes a deletion of an internal repetitive sequence, an inactive mutation in ICP47, and an inactive mutation in another copy of ICP4. A first antigen of the at least one antigen is driven by a promoter of an immediate early gene, such as ICP4. In particular examples, the HSV-1 viral vaccines express antigens from SARS-Cov, SARS-Cov-2, and variants thereof, and are used to induce an immune response against Sabebe virus in a subject to which the vaccine is administered.
Need to check novelty before this filing date? Find Prior Art